You are here

Article Text

Article menu
Download PDFPDF
Letter
Authors’ reply
  1. Y N Kallis1,
  2. M R Alison2,
  3. S J Forbes3
  1. 1
    Department of Medicine, St Mary’s Hospital Campus, Imperial College, London, UK
  2. 2
    Institute of Cell and Molecular Science, Queen Mary’s School of Medicine and Dentistry, London, UK
  3. 3
    Tissue Fibrosis and Remodelling Laboratory, MRC/University of Edinburgh Centre for Inflammation Research, Edinburgh, UK
  1. Dr S J Forbes, MRC/University of Edinburgh Centre for Inflammation Research, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK; stuart.forbes{at}ed.ac.uk

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We are grateful to Lyra et al for their recently published study showing the apparent safety of bone marrow (BM)-derived mononuclear cell injection for advanced liver cirrhosis.1 We agree that there is an urgent need to develop alternative treatments for liver cirrhosis given the worsening mismatch between the number of patients requiring a liver transplant and the number of organs available for transplantation.

    Stem cell therapy has the potential to benefit this group of patients. However, unlike a defined pharmacological treatment there is additional …

    View Full Text

    Linked Articles

    • Letter
      Bone marrow stem cells and liver disease
      Andre Castro Lyra Milena Botelho Pereira Soares Ricardo Ribeiro dos Santos Luiz Guilherme Costa Lyra
      Gut 2007; 56 1640-1640 Published Online First: 15 Oct 2007.